|
LIVE WEBINAR: Tuesday, November 11, 2025 | 5:00 PM – 6:00 PM Eastern Time (ET)
What Clinicians Want to Know: First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung CancerA CME/MOC-Accredited Live WebinarJoin us on Tuesday, November 11th for this CME/MOC-accredited webinar Faculty
Luis Paz-Ares, MD, PhD Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre Associate Professor at the Universidad Complutense Head of the Lung Cancer Unit at the National Oncology Research Center Madrid, Spain Misty Dawn Shields, MD, PhD Assistant Professor of Clinical Medicine Indiana University School of Medicine Adjunct Assistant Professor of Medical and Molecular Genetics Associate Member, Experimental and Developmental Therapeutics Department of Medicine, Division of Hematology/Oncology, Thoracic Oncology Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana
Moderator
Neil Love, MD Research To Practice Miami, Florida Tuesday, November 11, 2025 Topics to be announced. Target Audience Learning Objectives CE Credit Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Privacy Policy Unlabeled/Unapproved Uses Notice Content Validation and Disclosures FACULTY
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |